Gregory T. Lucier was Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion in 2014. During Mr. Lucier’s 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.
Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his 25+ years of strategic management experience to help champion an era of personalized medicine.
Kim Kamdar, Ph.D.
Kim Kamdar joined Domain Associates in 2005 and became a partner in 2011. With a background in small molecule drug discovery, Dr. Kamdar has been involved in cutting-edge therapeutic start-ups, using her expertise to identify companies with promising molecular and companion diagnostics that support personalized medicine.
Her present board memberships include Ariosa Diagnostics, Epic Sciences, Lithera, Obalon Therapeutics, ROX Medical, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. She was also involved with Corthera until its sale to Novartis in February 2010 and BiPar Sciences until its acquisition by Sanofi-Aventis in April 2009.
Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capita and a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.
Dr. Kamdar has authored ten papers and received seven patents. She completed her B.A. at Northwestern University and her Ph.D. in biochemistry and genetics at Emory University. Dr. Kamdar serves as an advisory board member of Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies. She is also a board member of San Diego's CONNECT Foundation and the Hastings Center.
John Sage is Chief of Staff to Melinda Gates and the Managing Director at Pivotal Ventures, the executive office Melinda established in 2015. Pivotal’s mission is to enhance and extend Melinda’s impact in the world. Its work includes innovation and incubation, venture investment and management, marketing and personal affairs management.
Prior to Pivotal, John directed stakeholder communications at the Gates Foundation, starting in 2011, and became Melinda’s foundation chief of staff the next year. This followed more than 20 years leading strategic initiatives for global companies — including the strategic plan for the Starbucks Foundation; helping launch the earliest versions of Office at Microsoft; and launching such properties as ESPN.com, and MLB.com, at web pioneer Starwave, culminating in its acquisition by Disney.
A pioneer in social justice marketing, in 1997 John cofounded Pura Vida Coffee, an organic fair-trade coffee company with distribution throughout the US. He is an Ashoka Fellow, an honor that recognizes entrepreneurs using business to transform society.
John received his MBA from Harvard University after earning a Bachelor of Arts with Honors from Stanford University.
Evgeny Zaytsev, M.D., Ph.D.
Dr. Evgeny Zaytsev is a managing partner at RMI Partners, the management company for RusnanoMedInvest. He was previously a general partner at Helix Ventures, which he co-founded to focus on investment in novel therapeutic opportunities. Prior to Helix, Dr. Zaytsev was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. Dr. Zaytsev has been involved in more than 30 investments in biomedical companies and is a board member of a number of companies in Silicon Valley and Russia. As an active business community leader, he founded and served as the first president of the US-Russia Technology Symposium at Stanford University (now Global Technology Symposium) and the annual Silicon Valley Open Doors investment conference.
Dr. Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. He received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993 from Altai State Medical University. Dr. Zaytsey also earned an MBA from the Stanford Graduate School of Business in 2002.
Gregory C. Critchfield, M.D.
Dr. Critchfield is chairman, president and CEO of Sera Prognostics, Inc. and the former president of Myriad Genetic Laboratories, Inc. He led its transformation into one of the world’s leading molecular diagnostics companies. Under his direction, Myriad Genetic Laboratories launched seven novel molecular diagnostic products across a variety of technology platforms, posting 52 percent compounded annual revenue growth from 1998 through 2010. Prior to joining Myriad, Dr. Critchfield was Chief Medical & Science Officer at Quest Diagnostics, Inc., overseeing medical affairs and innovation activities during its transition from Corning Clinical Laboratories.
He has also served on the faculty of three medical schools — University of Minnesota, Wayne State University, and Duke University — and was a practicing clinical pathologist with Intermountain Healthcare.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.